Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results
Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI Enrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by Q3 2026 Completed $80.5 million public offering supported by
(Financial Post, 2025-11-04T21:42:52Z)